Operating income · 2020–2025
Xeris Biopharma operating income
$24.9M+$58.5M · FY2025
Xeris Biopharma (XERS) reported $24.9M in operating income for fiscal 2025, +$58.5M from the year before.
Operating income — Operating income is profit from the core business before interest and tax. It strips out financing decisions, so it compares operations rather than balance sheets.
Every row links to its own SEC filing · Fiscal year 2025 · Data as of September 25, 2026
Operating income at companies of similar size
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Xeris Biopharma operating income |url=https://companiesranked.com/en/company/xeris-biopharma/operating-income |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Xeris Biopharma operating income. CompaniesRanked. https://companiesranked.com/en/company/xeris-biopharma/operating-incomeBibTeX
@misc{companiesranked-en-company-xeris-biopharma-operating-income-2026,
author = {{CompaniesRanked}},
title = {{Xeris Biopharma operating income}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/xeris-biopharma/operating-income}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001867096-26-000016 · March 2, 2026
{{cite web |title=Xeris Biopharma operating income — 10-K (0001867096-26-000016) |url=https://www.sec.gov/Archives/edgar/data/1867096/000186709626000016/xers-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-03-02}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.